Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus Vaccine Development
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag170 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Teeba Jihad und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines, Pfizer Research and Development, Pfizer, Inc, Pearl River, NewYork, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Vaccines, Cytomegalovirus Infections, Cytomegalovirus, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Inc.
Abstract (Originalsprache)
A human cytomegalovirus (CMV) vaccine to prevent congenital disease is a public health priority. We previously demonstrated that vaccine-elicited rhesus CMV (RhCMV) neutralizing titers and T-cell responses comparable to natural infection failed to protect from RhCMV infection after experimental oral challenge. Consequently, we established a natural transmission model in which newborn rhesus macaques are cohoused with their RhCMV-positive mothers and immunized 5 times between 0 and 24 months with glycoprotein B (gB), pentamer, pp65, and in 1 group viral interleukin 10. While no significant differences were observed in infection rate between the vaccine and placebo groups at 40 weeks after birth, partial protection was observed at week 52 (83.3% infection in placebo, 42.1%–50% in vaccine recipients). Within 14 weeks of juvenile macaques transfer to group housing, all shed RhCMV. These results suggest that the neonatal RhCMV natural transmission model may recapitulate observations in humans immunized with recombinant gB and can be a useful tool for evaluating CMV vaccine candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccines, Pfizer Research and Development, Pfizer, Inc, Pearl River, NewYork, USA.
- Pfizer Research Biostatistics, Collegeville, Pennsylvania, USA.
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Teeba Jihad, Helen Wang, Camille Robertson, Isis Kanevsky, Paul Liberator, Philip R Dormitzer, Nicholas J Buchkovich
Förderung
- Pfizer, Inc
Zitieren
APA
Jihad, T., Chi, X. S., He, Z., Lee, K., Needle, E., Loschko, J., Goymer, J., Wang, H., Boigard, H., Robertson, C., Obregon, J., Wilson, K., Kanevsky, I., Liberator, P., Matsuka, Y. V., Walter, M. R., Jansen, K. U., Yang, X., Dormitzer, P. R., …, & Buchkovich, N. J. (2026). Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus Vaccine Development. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag170
Vancouver
Jihad T, Chi XS, He Z, Lee K, Needle E, Loschko J, et al. Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus Vaccine Development. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag170
BibTeX
@article{Jihad2026,
author = {Jihad, Teeba and Chi, Xiaoyuan S and He, Zhiqing and Lee, Kwok and Needle, Elie and Loschko, Jakob and Goymer, Jessica and Wang, Helen and Boigard, Helene and Robertson, Camille and Obregon, Jennifer and Wilson, Kasey and Kanevsky, Isis and Liberator, Paul and Matsuka, Yury V and Walter, Mark R and Jansen, Kathrin U and Yang, Xinzhen and Dormitzer, Philip R and Swanson, Kena A and Buchkovich, Nicholas J},
title = {Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus Vaccine Development},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag170}
}
EUVIMED